EGF (Epidermal Growth Factor)
/ Recombinant human epidermal growth factor; EGFR ligandALIAS · rhEGF · Recombinant EGF · Heberprot-P (Cuban; intralesional formulation) · Easyef (Korean)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 2. Recombinant human EGF is approved in Cuba as Heberprot-P intralesional injection for severe diabetic foot ulcers (since 2006) and in Korea as Easyef topical solution for diabetic foot ulcer. Not FDA-approved in the United States. Phase 3 trials in Cuba and Korea support the regional approvals; vendor research-grade EGF protein sold by peptide suppliers is preclinical-grade material and is not pharmaceutically equivalent to the approved formulations.
Epidermal growth factor (EGF) is a 53-residue peptide originally isolated by Stanley Cohen (Nobel Prize 1986, shared with Rita Levi-Montalcini). EGF binds the epidermal growth factor receptor (EGFR / ERBB1), a receptor tyrosine kinase whose activation drives Ras-MAPK, PI3K-Akt, and PLC-gamma signalling, promoting epithelial cell proliferation, migration, and wound re-epithelialisation. In diabetic foot ulcer pharmacology, intralesional or topical EGF supplementation is hypothesised to compensate for impaired endogenous growth-factor signalling in the diabetic wound microenvironment, accelerating granulation and closure.
Tier 2. The Heberprot-P Phase 3 program in Cuba (Berlanga 2009 and subsequent registries) randomised severe diabetic foot ulcer patients to intralesional EGF versus placebo and reported higher complete granulation and reduced amputation rates. Korean studies of topical EGF (Easyef) in diabetic foot and other chronic wounds (Hong 2006 and others) supported the Korean approval. Western Phase 2 and Phase 3 trials of recombinant EGF for chronic wounds have produced more mixed results, contributing to the absence of FDA approval.
Heberprot-P intralesional injection has been associated with injection-site pain, burning, and chills in published trials; serious adverse events have been infrequent in the published Cuban registry. Topical EGF in Korean trials has been generally well tolerated. Theoretical concerns about EGFR-mediated proliferation and oncogenicity (EGFR is a recognised oncology target with multiple kinase inhibitors approved for EGFR-mutant cancers) have been a regulatory consideration but have not produced an observed clinical signal in the diabetic foot population in published follow-up.
Regulatory status
- FDA status:
- Not FDA-approved
- Compounding:
- Compounding eligibility ambiguous
The major translational gap is the difference between approved formulations (Heberprot-P intralesional vials, Easyef topical solution) manufactured under pharmaceutical GMP for human use, and vendor research-grade recombinant EGF protein sold by peptide suppliers, which has no human pharmaceutical specification. Western trials of EGF for chronic wounds have not consistently replicated the Cuban Heberprot-P results, and the reasons (formulation, delivery, patient selection, endpoint definition) are debated. EGFR oncology signalling remains a theoretical concern even with localised dosing.